
SpliSense Secures $13 Million for Cystic Fibrosis Drug Trial
A successful Phase 2a trial for a novel inhaled therapy has triggered a $13 million investment from the Cystic Fibrosis Foundation. The funding will accelerate clinical development of SPL84, an antisense oligonucleotide designed to treat patients with the specific 3849+10kb C→T genetic mutation who currently lack effective treatment options.






















